The DOI matches its Crossref record.
Biologics in the treatment of uveitis
Abstract
PURPOSE OF REVIEW: This review summarizes the current evidence for biologic therapies in the treatment of uveitis. The review emphasizes published research in this field since 2005. RECENT FINDINGS: The anti-tumour necrosis factor-alpha infliximab and adalimumab have demonstrated significant efficacy in controlling uveitis associated with seronegative spondyloarthropathies and juvenile idiopathic arthritis; however, etanercept has failed to show a similar treatment effect in uveitis associated with these conditions. The majority of reports of biologic therapies in posterior uveitis have been uncontrolled trials, or retrospective studies, of uveitis resistant to immunosuppression. Encouragingly, successful control of such refractory intraocular inflammation has been consistently reported with infliximab and interferon alpha, particularly Behcet's disease-associated uveitis. A limited number of reports of anti-interleukin therapies, daclizumab and anakinra, have supported a role for these therapies in some types of uveitis. SUMMARY: Biologic therapies have increased the treatment options for sight-threatening uveitis. Despite experimental rationale, the lack of evidence from randomized controlled studies limits our understanding of when to commence therapy, which agent to choose and how long to continue treatment. Additionally, the high cost and potential side effects of all biologic agents have limited their current use to uveitis refractory to immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
A look at autoimmunity and inflammation in the eye
Caspi, R. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42440 · Cited by 482
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Ramanan, A. V., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot-Lacassagne, S., Hardwick, B., Hickey, H., Hughes, D., Woo, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614160 · Cited by 437
Self-citationUnderstanding uveitis: The impact of research on visual outcomes
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Miserocchi, E., Murray, P. I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., & Lightman, S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.005 · Cited by 340
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease
Raveney, B. J. E., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.10.1390 · Cited by 39
Self-citation
Metadata
- Authors
- Imrie, F. R., & Dick, A. D.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2007-11
- Volume
- 18
- Issue
- 6
- Pages
- 481-486
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W2026629764
- Cited by
- 160
- References
- 0
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biologics in the treatment of uveitis. https://app.cochat.ai/papers/10.1097/icu.0b013e3282f03d42
- The paper
- Imrie, F. R., & Dick, A. D. (2007). Biologics in the treatment of uveitis. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0b013e3282f03d42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.